Personalized Cancer Vaccine Shows Promise In Major Trial
Top Story
Archived
•
October 24, 2026
•
Pharmaceutical companies Merck and Moderna reported that an experimental personalized mRNA vaccine, given alongside the immunotherapy drug Keytruda, reduced the risk of melanoma recurrence or death by 42% compared with Keytruda alone. The Phase 3 trial included 1,137 patients with Stage IIB-IV melanoma whose tumors had been surgically removed. The findings could bring the drugmakers ...
Source: Daily Wire | https://www.dailywire.com/feeds/rss.xml - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!



